Korea's arms agency ties a full merger review to any Hanwha seat on KAI's board

Seoul Economic Daily reports that the FTC shares DAPA's position ^[11], but the two agencies have published different lines. "Even if one company acquires shares in another, if that does not create a controlling relationship, it is deemed to pose no restriction on competition and is excluded from a full review," a DAPA official said ^[8]. The official added, "But if Hanwha's move to secure managerial control becomes formalized, such as by entering the board through the appointment of directors, it will become subject to a full merger review" ^[7].

Under DAPA's test, one formalized director is enough ^[1]. Under the FTC's written condition, Hanwha's count has to reach one-third of KAI's executive posts ^[4]. A single Hanwha appointee could satisfy the first test and fall short of the second.

DAPA's role in a merger review is to advise. The official said the agency "plans to apply strict standards and to present a formal opinion to the competition authorities and respond accordingly" ^[10]. Its harder tool is Article 35 of the Defense Business Act, under which DAPA's consent is also required when control of a defense contractor changes, according to the report ^[13]. Add up the FTC's full review, the trade minister's prior approval and the minister's consultation with DAPA, and control of KAI needs three sign-offs ^[16]. The shares cleared on Aug. 31 with one simplified review and no separate objection from DAPA ^[3][2][5].

The scope of a full review is wider than the two companies. "In that case, we can conduct a review of competition restrictions, including conflicts of interest," the official said ^[17]. The official described what a formal appointment would trigger: "Once the appointment of directors takes concrete shape and is formalized, that amounts to substantive involvement in management, and it could constitute vertical and horizontal restrictions on competition between Hanwha and KAI, and between Hanwha and its competitors" ^[9].

The stake can go one of three ways from here. Hanwha can stay the second-largest shareholder without a seat ^[6], holding shares the FTC has already judged unable to exert substantive influence over management ^[2]. It can name directors and take a full review with a DAPA opinion attached ^[7][10]. Or it can keep buying toward the top holding, which is the FTC's own trigger ^[4]. According to Seoul Economic Daily, some analysts see the purchase as groundwork for control, and some in the defense industry expect Hanwha figures to take part in the board in earnest ^[15]. The report does not give the size of Hanwha's stake or what it paid, so the regulatory cost of each path cannot yet be set against the price of the shares.

In my view the regulatory risk in this deal sits on the path to control, and the stake has already cleared its part ^[16][2]. Until Hanwha names a director, its money is in a holding that the competition authority has found cannot steer KAI. The counter-case is that DAPA was answering a query from the office of Rep. Min Hong-chul ^[14], and on competition its role ends at an opinion ^[10]. If Hanwha places a director and the FTC clears the appointment without a full review, that view is wrong.